Regulatory information
Nazaré (Belgium)/Rotterdam (Netherlands), 27 September 2022 – 8am CET

Faglon commits to setting science-based emission reduction targets

Fagron, a global leader in pharmaceutical compounding, has set science-based emission reduction targets to meet the Paris Agreement goal of limiting global warming to 1.5, and has identified these as the Science-Based Targets Initiative (SBTi). announced that it has promised to verify by C.

Fagron CEO Rafael Padilla said:
“By committing to set science-based targets, Fagron is committed to building a future-ready organization with a clear focus on sustainability, one of Fagron’s four strategic goals. take a big step forward. This will strengthen our efforts to comply with the Paris Agreement and our contribution to limiting global warming. Corporate social responsibility is at the heart of what we do. Personalizing healthcare makes healthcare accessible to more people. In our efforts to contribute to a better world, we are proud to be committed to emissions reduction targets independently verified by SBTi.”

SBTi is a partnership of CDP, the United Nations Global Compact, the World Resources Institute, and the World Wide Fund for Nature to define and promote best practices for climate science-aligned emission reductions and net-zero targets. SBTi is a key partner in the Business Ambition for 1.5°C campaign, mobilizing businesses to set goals in line with a 1.5°C future.

As part of its commitment to SBTi, Faglon sets and verifies greenhouse gas emission reduction targets for Scope 1, 2 and 3 emissions in line with SBTi criteria. Fagron will report company-wide emissions and disclose progress against targets annually.

For more information on SBTi and Fagron commit considerations, see Fagron’s website.

Further information
Karen Berg
Global Investor Relations Manager
Phone +31 6 53 44 91 99
karen.berg@fagron.com

About Fagron
Fagron is one of the world’s leading active pharmaceutical compounding companies, with a focus on providing personalized medicines to hospitals, pharmacies, clinics and patients in 35 countries around the world.

Belgian company Fagron NV has a registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, headquartered in Rotterdam.

In the event of any discrepancies between the English translation of this press release and the Dutch original, the latter shall prevail.

For the press release, please open the link below.
Faglon commits to setting science-based emission reduction targets